% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{DeSaintHubert:284430,
author = {M. De Saint-Hubert and G. Boissonnat and U. Schneider and
C. Bäumer$^*$ and N. Verbeek and J. Esser and J. Wulff and
F. Stuckmann and F. Suesselbeck and R. Nabha and J. Dabin
and F. Vasi and S. Radonic and M. Rodriguez and A. C. Simon
and N. Journy and B. Timmermann$^*$ and I. Thierry-Chef and
L. Brualla$^*$},
title = {{C}omplete patient exposure during paediatric brain cancer
treatment for photon and proton therapy techniques including
imaging procedures.},
journal = {Frontiers in oncology},
volume = {13},
issn = {2234-943X},
address = {Lausanne},
publisher = {Frontiers Media},
reportid = {DKFZ-2023-02014},
pages = {1222800},
year = {2023},
abstract = {In radiotherapy, especially when treating children,
minimising exposure of healthy tissue can prevent the
development of adverse outcomes, including second cancers.
In this study we propose a validated Monte Carlo framework
to evaluate the complete patient exposure during paediatric
brain cancer treatment.Organ doses were calculated for
treatment of a diffuse midline glioma (50.4 Gy with 1.8 Gy
per fraction) on a 5-year-old anthropomorphic phantom with
3D-conformal radiotherapy, intensity modulated radiotherapy
(IMRT), volumetric modulated arc therapy (VMAT) and
intensity modulated pencil beam scanning (PBS) proton
therapy. Doses from computed tomography (CT) for planning
and on-board imaging for positioning (kV-cone beam CT and
X-ray imaging) accounted for the estimate of the exposure of
the patient including imaging therapeutic dose. For dose
calculations we used validated Monte Carlo-based tools
(PRIMO, TOPAS, PENELOPE), while lifetime attributable risk
(LAR) was estimated from dose-response relationships for
cancer induction, proposed by Schneider et al.Out-of-field
organ dose equivalent data of proton therapy are lower, with
doses between 0.6 mSv (testes) and 120 mSv (thyroid), when
compared to photon therapy revealing the highest
out-of-field doses for IMRT ranging between 43 mSv (testes)
and 575 mSv (thyroid). Dose delivered by CT ranged between
0.01 mSv (testes) and 72 mSv (scapula) while a single
imaging positioning ranged between 2 μSv (testes) and 1.3
mSv (thyroid) for CBCT and 0.03 μSv (testes) and 48 μSv
(scapula) for X-ray. Adding imaging dose from CT and daily
CBCT to the therapeutic demonstrated an important
contribution of imaging to the overall radiation burden in
the course of treatment, which is subsequently used to
predict the LAR, for selected organs.The complete patient
exposure during paediatric brain cancer treatment was
estimated by combining the results from different Monte
Carlo-based dosimetry tools, showing that proton therapy
allows significant reduction of the out-of-field doses and
secondary cancer risk in selected organs.},
keywords = {Monte Carlo simulation (Other) / imaging dosimetry (Other)
/ out-of-field dosimetry (Other) / photon radiotherapy
(Other) / proton therapy (Other) / secondary cancer risk
(Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37795436},
pmc = {pmc:PMC10546320},
doi = {10.3389/fonc.2023.1222800},
url = {https://inrepo02.dkfz.de/record/284430},
}